MVP 7.61% 42.5¢ medical developments international limited

Ann: 2024 Half Year Announcement, page-30

  1. 1,641 Posts.
    lightbulb Created with Sketch. 123
    the issue to me is that volume sales have only ever been achieved through ambos. Yet MVP persist in trying to sell outside of that scenario. They have been trying to sell into EDs and other in the UK for over 8 years and have barely delivered 20% of the volumes against 3 times the population. And those wins are expensive which comes through in the lack of profits despite distribution costs being managed by Galen.

    they should be spending all their time and effort trying to get into ambo trusts and nothing else.

    even here in our home market the Emergency ward/other strategy is a failure. 12 months with 4% increase in sales??

    this is not rocket science. Pull back on every market - lobby the right people and get into regular use in ambos. Anything else is doomed to fail
 
watchlist Created with Sketch. Add MVP (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.